Company Description
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need.
Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.
The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors.
It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities.
The company is headquartered in Houston, Texas.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2 |
| CEO | David Arthur |
Contact Details
Address: 2450 Holcombe Boulevard, Suite X Houston, Texas 77021 United States | |
| Phone | 832 834 9144 |
| Website | salariuspharma.com |
Stock Details
| Ticker Symbol | SLRX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001615219 |
| CUSIP Number | 79400X107 |
| ISIN Number | US79400X3052 |
| Employer ID | 46-5087339 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| David J. Arthur M.B.A. | Chief Executive Officer, President and Director |
| Mark J. Rosenblum CPA | Executive Vice President of Finance and Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 1, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Nov 1, 2024 | DEF 14A | Other definitive proxy statements |
| Sep 27, 2024 | 8-K | Current Report |
| Aug 15, 2024 | 8-K | Current Report |
| Aug 14, 2024 | 8-K | Current Report |
| Aug 9, 2024 | 10-Q | Quarterly Report |
| Jul 25, 2024 | 8-K | Current Report |
| Jul 25, 2024 | 424B5 | Filing |